The 2010s: A Decade Of Acceleration, Innovation And Controversy
Oncology And Rare Diseases Boom
A look back at some of the defining events and trends in pharma over the past 10 years.
You may also be interested in...
The FDA has overcome doubts about the drug's safety and reversed its decision in just four months.
Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.
The partners are halting recruitment out of “an abundance of caution,” but Gilead could decide to exit the alliance if islatravir cannot shake off safety concerns.